澳大利亚的GLP-1减肥药市场正经历快速扩张，但大量非官方供应渠道的出现引发了严重的监管和安全问题。根据新南威尔士大学2025年11月发布的研究，澳大利亚约2%的人口（每1000人中18人）定期使用GLP-1药物1。销售数据显示，这类药物的处方量从2020年5月的58,000增长到2025年4月的500,0001，增幅超过8倍。然而，在2025年4月的估计使用量中，经私人非补贴渠道获取的占比达43.8%，患者需要支付高达每月600澳元的费用1。
非正规供应渠道的泛滥带来了产品安全风险。澳大利亚药品监管局（TGA）在3月发现多种进口产品标注为GLP-1药物但实际不含相关成分1。本月早些时候，TGA与新南威尔士警察合作查获价值超过120,000澳元的未批准肽类和合成代谢类固醇产品1。更令人担忧的是，维多利亚州卫生部门报告自1月以来出现6起与使用标注为retatrutide产品相关的急性肝损伤病例1。此外，在2022年末至2024年初期间，由于药物短缺，GLP-1药物销售曾下降近80%1，这一供应中断进一步驱使消费者转向非正规市场寻求替代品。
Australia's market for GLP-1 weight-loss medications has experienced explosive growth, but the expansion has been shadowed by an alarming proliferation of unregulated supply routes. According to research released by the University of New South Wales in November 2025, approximately 18 per 1,000 Australians—roughly 2 percent of the population—now regularly use GLP-1 drugs 1. Sales of these medications surged from 58,000 units in May 2020 to 500,000 units by April 2025 1. However, private, unsubsidized access has become increasingly prevalent, accounting for an estimated 43.8 percent of total usage by April 2025, with consumers paying up to $600 per month 1.
The regulatory landscape has become increasingly fraught as consumers seek medications through unofficial channels, including social media marketers and Thai beauty clinics 1. The Therapeutic Goods Administration (TGA) discovered multiple imported products labeled as GLP-1 compounds that contained no such active ingredients in March 1. More concerningly, the TGA and New South Wales police jointly seized unapproved peptide and anabolic steroid products valued at over $120,000 earlier this month 1. Victoria's health department has documented six cases of acute liver injury linked to products marketed as retatrutide since January 1.
Supply disruptions have also characterized the market during the research period spanning 2020 to 2025, with sales declining by nearly 80 percent between late 2022 and early 2024 due to medication shortages 1.
评论
还没有评论，欢迎留下第一条。